Table 3:

Out-of-pocket costs ($US dollars) by treatment approach, chemotherapy regimen, and inclusion of bevacizumab (n = 12,761)

	n (%)	Unadjusted out-of-pocket costs		Adjusted out-of-pocket costs*
		Median	Mean	Mean	95% CI	p
Primary debulking	11,091 (87%)	$2111	$3021	$2977	$2923 – $3031	<.001
Neoadjuvant chemotherapy	1670 (13%)	$1489	$2367	$2519	$2403 – $2640
Chemotherapy regimen
IV standard	9739 (76%)	$1982	$2870	$2838	$2784 – $2893	<.001
IV dose-dense	1679 (13%)	$2103	$3279	$3405	$3250 – $3571
IP/IV	1343 (11%)	$2145	$2981	$2888	$2742 – $3042
Regimens without bevacizumab	11,912 (93%)	$1982	$2917	$2898	$2848 – $2948	<.001
Regimens with bevacizumab	849 (7%)	$2449	$3197	$3127	$2931 – $3336

IV: Intravenous; IP: Intraperitoneal

^*Costs were adjusted for age, Charlson comorbidity index, region of care, insurance plan, and year of diagnosis